特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
948545

薬価・医療費償還:世界市場

Pharmaceutical Pricing and Reimbursement: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 164 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
薬価・医療費償還:世界市場
出版日: 2020年07月09日
発行: BCC Research
ページ情報: 英文 164 Pages
納期: 即納可能 即納可能とは
担当者のコメント
COVID-19の感染症拡大の影響下における、各国別の薬価・医療費償還制度とその市場、価格設定メカニズム、価格設定戦略及び償還戦略などの調査結果をまとめた最新の調査レポートが米国BCC Researchよりリリースされました。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品市場規模は、2019年の1兆580億米ドルから、2024年までに1兆5200億米ドルへ達すると予測され、2019年から2024年にかけては、7.5%のCAGRが見込まれています。

当レポートでは、世界の医薬品市場における薬価・医療費償還について調査し、過去10年間の世界の医薬品市場における医療制度改革と規制、それらが業界のM&A、ベンチャーキャピタリスト投資へ及ぼす影響などの分析、米国・欧州における薬価設定・医療費償還の政策・プロセス、およびジェネリック医薬品、バイオシミラー、市販薬(OTC)、小分子、生物学的製剤への医薬品投資の方法のレビューなどを提供しています。

第1章 イントロダクション

  • 研究の目標と目的
  • 調査理由
  • レポートの範囲
  • 情報ソース
  • 調査手法
  • 地域内訳
  • アナリストの経歴
  • BCCのカスタムリサーチ
  • BCC Research 関連レポート

第2章 サマリー・ハイライト

第3章 世界のヘルスケア支出、法律および価格設定メカニズム

  • 世界のヘルスケアコスト
  • COVID前の予測
  • COVID後の予測
  • COVID-19に対する急患治療の対応
  • 低コストのデジタルサービスの拡大
  • COVID-19向け研究開発の資金
  • 医薬品支出
  • 北米
  • 欧州
  • 日本
  • BRIC
  • 2020年第1四半期の医薬品売上に対するCOVID-19の影響
  • 合併と買収(M&A)
  • 2019年以前のM&A活動
  • 2019年のM&A活動
  • 2020年第1四半期のM&A活動
  • ヘルスケア改革
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 米国
  • 医薬品規制
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 米国
  • ヘルスケアに対するCOVID-19の急性的影響
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 米国

第4章 価格設定戦略

  • イントロダクション
  • 医薬品コスト上昇の主な理由
  • 古い、低コストの医薬品から新しい、より高価な薬への置き換え
  • 医薬品の使用増加
  • これまで治療薬がなかった疾患の新薬
  • 既存薬の価格の上昇
  • 医薬品の価格設定戦略
  • 外部価格参照
  • 内部参照価格
  • 処方薬の価格
  • 英国
  • 米国
  • 市販(OTC)薬の価格
  • 欧州
  • 英国
  • 米国
  • ジェネリック医薬品の価格
  • 英国
  • 米国
  • 希少薬の価格
  • バリューベースプライシング(value-based pricing:価値に基づく価格設定)
  • 公開入札の招待と調達
  • フレームワーク合意方式/枠組み協定(Framework Agreement)

第5章 医療費償還戦略

  • 医薬品償還
  • 医療費償還の承認
  • 医療費償還手続き
  • 欧州
  • 英国
  • 米国
  • 病院の医療費償還
  • 欧州
  • 英国
  • 米国
  • 患者アクセススキーム
  • 財務ベーススキーム
  • 結果ベーススキーム
  • 医薬品スキームへの早期アクセス
  • 欧州
  • 英国
  • 米国
  • 処方リスト
  • 欧州
  • 英国
  • 米国
  • 医療技術評価(HTA)
  • 欧州
  • 英国
  • 米国
  • アウトカムリサーチ(HEOR)の価値
  • HEOR トップ10動向

第6章 将来

  • バリューベースプライシングスキームの採用拡大
  • 細胞・遺伝子治療への投資の増加
  • 革新的な支払いモデル
  • Brexitがより明確に
  • 薬価をめぐる政治的論争
  • COVID-19に対する長期的な対応は不明確

第7章 参考資料

図表

List of Tables

  • Table 1 : Major Market Drivers of Global Healthcare Expenditures
  • Table 2 : Total Healthcare Expenditure in G20 Economies, 2018
  • Table 3 : Inpatient Care Average Length of Stay in All Hospitals, 2014
  • Table 4 : Steps Implemented to Access Diagnostics and Treatment Following the COVID-19 Pandemic
  • Table 5 : Steps Implemented to Boost and Optimize Healthcare Capacity
  • Table 6 : COVID-19 Vaccines under Development
  • Table 7 : COVID-19 Treatments under Development
  • Table 8 : Major Mergers and Acquisitions in the Global Pharmaceutical Market, 2019
  • Table 9 : Major M&A Deals in the Global Pharmaceutical Market, Q1 2020
  • Table 10 : Allowed Growth Rates, 2014-2018
  • Table 11 : Net Revenues Retained in the U.S. Pharmaceutical Market, by Type of Prescription Drug Participant, 2016
  • Table 12 : Pricing of Medicines in Europe
  • Table 13 : Using Market Forces to Price Generics in the U.K.
  • Table 14 : Pricing Policies for Biosimilars in Europe, as of April 2017
  • Table 15 : National Authorities in Charge of Market Authorization, Pricing and Reimbursement in the EU5 Countries
  • Table 16 : Federally Funded Health Insurance Programs in the U.S.
  • Table 17 : An Overview of Early Access Schemes
  • Table 18 : Example of a Five-Tier Formulary System in the U.S.
  • Table 19 : Acronyms Used in the Global Pharmaceutical Pricing and Reimbursement Market

List of Figures

  • Figure 1 : Projected Annual Growth in Global Healthcare Spending, 2020
  • Figure 2 : Global GDP Growth Forecast Comparison, February 2020 vs. May 2020
  • Figure 3 : Overview of Coronavirus Impact Index, by Industry
  • Figure 4 : Potential Initial Impact of Partial or Complete Shutdowns on Activity in the G7 Economies
  • Figure 5 : Schematic Diagram of Global Healthcare Spend to Increase, 2020
  • Figure 6 : Trends in Global Pharmaceuticals Sales, by Market Segment, 2018-2024
  • Figure 7 : Projected Annual Growth Forecast in Global Pharmaceutical Market, by Region Group, 2018-2022
  • Figure 8 : Market Shares of Generic Medicine Sales in Selected European Countries, as of 2016
  • Figure 9 : Cumulative Pharmaceutical M&A Spending Comparison, 2019 vs. 2018
  • Figure 10 : Healthcare Reforms in Germany
  • Figure 11 : Worldwide Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 12 : Regional Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 13 : European Countries Where External Reference Pricing is Used
  • Figure 14 : Overview of Countries that Refer to the U.K.
  • Figure 15 : European Countries Where Internal Reference Pricing is Used
  • Figure 16 : NHS Spending on Prescription Pharmaceuticals, 2010-2018
  • Figure 17 : Pharmaceutical Pricing Process in the U.S.
  • Figure 18 : Countries Using Generic Prices in Europe
  • Figure 19 : Share of Generic Drug Sales (by Value and Volume) Across the OECD Nations, 2014
  • Figure 20 : Comparing Prices of Biosimilars and Branded Products
  • Figure 21 : U.S., EU and Japan Orphan Designations per Year and Cumulative, 1983-2016
  • Figure 22 : Top 100 Orphan Drug Costs per Patient per Year in the U.S., 2012-2016
  • Figure 23 : Value-Based Pricing Process in the U.K.
  • Figure 24 : Overview of Pharmaceutical Tendering Process
  • Figure 25 : Overview of the Application of Reimbursement Schemes in Europe
  • Figure 26 : Organization of the U.S. Healthcare System
  • Figure 27 : U.S. Healthcare Expenditures as a Share of GDP, by Source of Funds, 1987-2018
  • Figure 28 : Organization of the Healthcare System in England
  • Figure 29 : Evolution of PAS England, 2007-2015
  • Figure 30 : PAS Approval Process (Simplified Version)
  • Figure 31 : Pathways for Accessing an Orphan Therapy in the EU
  • Figure 32 : Three-Stage EAMS Process in the U.K.
  • Figure 33 : Types of Reimbursement Lists Used in the Outpatient Sector Europe
  • Figure 34 : Process of Identifying if an Item Can be Prescribed on the NHS
  • Figure 35 : Two Simplified Examples of HTA Utilization in Europe
  • Figure 36 : Tools and Disciplines Involved HEOR Analysis
  • Figure 37 : Elements of Value-Based Pricing
  • Figure 38 : Global Cell and Gene Therapy Market, 2018 vs. 2024
  • Figure 39 : Innovative Payment Models for Cell and Gene Therapies
  • Figure 40 : Four Waves of COVID-19 on Healthcare
目次
Product Code: PHM189A

Highlights:

The global pharmaceuticals market was valued at $1,058 billion in 2019 and should reach $1,520 billion by 2024 with a compound annual growth rate (CAGR) of 7.5% from 2019 to 2024.

Report Scope:

This new report on pricing and reimbursement in a global market provides a brief overview on the pharmaceutical markets, healthcare reforms and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.

Report Includes:

  • An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures
  • Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry
  • Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing
  • Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace
  • Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms

  • Global Healthcare Costs
  • Forecasts Pre-COVID
  • Forecasts Post-COVID
  • Acute Healthcare Response to COVID-19
  • Expansion of Low-Cost Digital Services
  • Funding for COVID-19 Research and Development
  • Drug Expenditures
  • North America
  • Europe
  • Japan
  • BRIC Economies
  • Impact of COVID-19 on Pharmaceutical Sales in Q1 2020
  • Mergers and Acquisitions (M&A)
  • M&A Activity Pre-2019
  • M&A Activity in 2019
  • M&A Activity in Q1 2020
  • Healthcare Reforms
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Pharmaceutical Regulation
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Acute Impact of COVID-19 on Healthcare
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States

Chapter 4 Pricing Strategies

  • Introduction
  • Primary Reasons for the Rise in the Cost of Pharmaceuticals
  • Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs
  • Increased Use of Drugs
  • New Drugs for Diseases for Which No Treatment Was Previously Available
  • Increases in the Prices of Existing Medicines
  • Pharmaceutical Pricing Strategies
  • External Price Referencing
  • Internal Referencing Pricing
  • Prescription Drug Pricing
  • United Kingdom
  • United States
  • Over-the-Counter (OTC) Drug Pricing
  • Europe
  • United Kingdom
  • United States
  • Generic Drug Pricing
  • United Kingdom
  • United States
  • Orphan Drug Pricing
  • Value-Based Pricing
  • Open Tender Invitations and Procurement
  • Framework Agreements

Chapter 5 Reimbursement Strategies

  • Pharmaceutical Reimbursement
  • Admission to Reimbursement
  • Reimbursement Procedure
  • Europe
  • United Kingdom
  • United States
  • Hospital Reimbursement
  • Europe
  • United Kingdom
  • United States
  • Patient Access Schemes
  • Financially Based Schemes
  • Outcome-Based Schemes
  • Early Access to Medicines Schemes
  • Europe
  • United Kingdom
  • United States
  • Formulary Lists
  • Europe
  • United Kingdom
  • United States
  • Health Technology Assessments (HTA)
  • Europe
  • United Kingdom
  • United States
  • The Value of Health Economics and Outcome Research (HEOR)
  • Top 10 HEOR Trends

Chapter 6 The Future

  • Greater Adoption of Value-Based Pricing Schemes
  • Increased Investment in Cell and Gene Therapies
  • Innovative Payment Models
  • Greater Clarity on Brexit
  • Political Wrangling Over Drug Prices
  • Long-term Response to COVID-19 Undefined

Chapter 7 References

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.